Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer.
Chemoradiotherapy has been shown to improve survival over radiation alone for unresectable locally advanced non-small cell lung cancer (NSCLC). Large randomized trials comparing sequential to concomitant platinum based chemoradiotherapy have demonstrated improved median survival times in favor of concomitant treatment. Recent phase II trials have evaluated the integration of advanced radiotherapy techniques, novel chemotherapy combinations, induction chemotherapy, and consolidation chemotherapy with concomitant chemoradiotherapy. On-going or recently completed phase III trials are evaluating whether the promising regimens from phase II studies are superior to concomitant chemoradiotherapy alone. Molecular therapies now need to be integrated with chemoradiotherapy.
Ready
Neal E
NE
Brown University Medical School, Providence, RI, USA. neready@lifespan.org
Vokes
Everett E
EE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D066246:ErbB Receptors; D002945:Cisplatin